Cangrelor for reducing atherothrombotic events in people undergoing percutaneous coronary intervention or awaiting surgery requiring interruption of anti‑platelet therapy (terminated appraisal)
Technology appraisal
Reference number: TA351
Published:
History
A list of downloadable documents created during development.
Coronary heart disease - cangrelor: draft scope for consultation (pre-referral) - November 2013